Yes. We can’t report the results until we patent and we can’t justify the patenting costs unless we know bisantrene will affect m6A RNA levels in patients.
Yes. We can’t report the results until we patent and we can’t...
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.035(2.18%) |
Mkt cap ! $266.3M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.62 | $1.56 | $101.6K | 64.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7451 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 408 | 1 |
View Market Depth
| Last trade - 15.53pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.58 |
Change
-0.035 ( 1.25 %) |
||||
| Open | High | Low | Volume | ||
| $1.58 | $1.62 | $1.56 | 7255 | ||
| Last updated 15.57pm 05/06/2024 ? | |||||
| RAC (ASX) Chart |